- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Liquidia Technologies today announced that the company's Founder, Dr. Joseph DeSimone, has been invited to join an elite list of speakers that will present at this year's TEDMED Conference being held in San Diego, California October 25 -28. Dr. DeSimone's presentation titled "CAN NANOTECHNOLOGY DELIVER MEGA RESULTS?" will explore the latest advancements in nanomedicine, including PRINT Technology, which represents a new frontier in the development of highly innovative vaccines and life saving therapeutics.
TEDMED is an annual conference where cutting-edge science and technology leaders "connect, understand, and inspire" to advance the art of health and medicine with new ideas. The conference's roster includes more than 50 preeminent leaders including the winner of a Nobel Prize in Chemistry, Dr. Peter Agre, and the U.S. Surgeon General, Dr. Regina Benjamin.
Dr. DeSimone's presentation will be available following the conference at www.liquidia.com. TEDMED also makes available all of its stage presentations at www.tedmed.com at no cost after the conclusion of the conference.
About Liquidia Technologies
Liquidia Technologies is developing precisely engineered particles for improved delivery of biologics and small molecules for vaccine and therapeutic applications. The ability to control particle design parameters such as size, shape and chemistry is allowing Liquidia to potentially address critical unmet needs in the prevention and treatment of human disease. In addition to its own products, Liquidia licenses its PRINT® particle technology and its GMP manufacturing capabilities to support proprietary programs advanced by collaborators.
The PRINT (Particle Replication In Non-Wetting Templates) technology platform offers the first GMP platform for designing and fabricating monodisperse particles with precise, reproducible dimensions. For a given vaccine or therapeutic application, PRINT particles can be designed to control the presentation of the biologic or small molecule or molecules in an effort to optimize the cell/tissue selectivity, release kinetics and ultimately the pharmacodynamics of a given therapy. Ultimately, precise control of particle design could transform the way drugs are developed, including more effective and less toxic therapeutics and vaccines. Liquidia initiated its first Phase 1 clinical trial in 2010 and has developed a portfolio of vaccine programs that are currently in early preclinical development.
The company was co-founded in 2004 by Dr. Joseph DeSimone and is located in Research Triangle Park, North Carolina.
ABOUT DR. JOSEPH DESIMONE
Joseph DeSimone is the Chancellor’s Eminent Professor of Chemistry at the University of North Carolina at Chapel Hill and William R. Kenan Jr. Professor of Chemical Engineering at North Carolina State University. DeSimone is also an Adjunct Member at Memorial Sloan-Kettering Cancer Center in New York. DeSimone has published over 270 scientific articles and has 120 issued patents in his name with over 120 patents pending. In 2005, DeSimone was elected into the National Academy of Engineering and the American Academy of Arts and Sciences.
DeSimone has received over 40 major awards and recognitions including the 2010 AAAS Mentor Award, the 2009 NIH Director’s Pioneer Award, the 2009 North Carolina Award, and the 2008 Lemelson-MIT Prize for Invention and Innovation.
DeSimone received his BS in Chemistry in 1986 from Ursinus College in Collegeville, PA and his Ph.D. in Chemistry in 1990 from Virginia Tech.
For more information, please click here
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016